{"filing":{"accession_number":"0001867096-26-000045","cik":"0001867096","ticker":"XERS","company_name":"Xeris Biopharma Holdings, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"xers-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/xers-20260610.htm"},"events":[{"id":5551,"run_id":4870,"accession_number":"0001867096-26-000045","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Xeris Biopharma is issuing shares of common stock in a private placement to noteholders exchanging approximately $23 million in principal amount of convertible notes under Section 4(a)(2) exemptions, representing a dilutive equity issuance that materially affects shareholder ownership.","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6086,"accession_number":"0001867096-26-000045","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Xeris Biopharma is issuing shares of common stock in a private placement to noteholders exchanging approximately $23 million in principal amount of convertible notes. The shares will be issued unregistered under Section 4(a)(2) of the Securities Act in reliance on accredited investor and qualified institutional buyer exemptions. This represents a dilutive equity issuance that would materially affect shareholder ownership and is a classic Item 3.02 disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:17:10.530682+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5552,"run_id":4870,"accession_number":"0001867096-26-000045","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Xeris Biopharma has entered into Exchange Agreements with noteholders, announced on June 11, 2026, involving material corporate transactions and exchange consideration that materially affect investors.","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6087,"accession_number":"0001867096-26-000045","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into \"Exchange Agreements\" with associated \"Exchange Consideration\" and contemplated transactions, announced via press release on June 11, 2026. While the specific details of the exchange are not fully elaborated in this excerpt, the language \"entry into the Exchange Agreements\" and reference to \"transactions contemplated thereby\" indicates a material corporate transaction. The forward-looking statements section emphasizes the significance of the Exchange and its timing, consistent with M\u0026A or significant capital restructuring activity that would materially affect investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:17:10.530682+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6086,"accession_number":"0001867096-26-000045","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Xeris Biopharma is issuing shares of common stock in a private placement to noteholders exchanging approximately $23 million in principal amount of convertible notes. The shares will be issued unregistered under Section 4(a)(2) of the Securities Act in reliance on accredited investor and qualified institutional buyer exemptions. This represents a dilutive equity issuance that would materially affect shareholder ownership and is a classic Item 3.02 disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:17:10.530682+00:00","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-11"},{"id":6087,"accession_number":"0001867096-26-000045","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into \"Exchange Agreements\" with associated \"Exchange Consideration\" and contemplated transactions, announced via press release on June 11, 2026. While the specific details of the exchange are not fully elaborated in this excerpt, the language \"entry into the Exchange Agreements\" and reference to \"transactions contemplated thereby\" indicates a material corporate transaction. The forward-looking statements section emphasizes the significance of the Exchange and its timing, consistent with M\u0026A or significant capital restructuring activity that would materially affect investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:17:10.530682+00:00","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-11"}]}